In the QUANTUM-R trial for patients with R/R FLT3-ITD AML, single-agent quizartinib was found to significantly improve the median OS from 4.7 months to 6.2 months compared with the investigators choice of treatment. Here, FLT3 is linked to acute myeloid leukemia.